Sector News

Bristol-Myers boosts I-O offering with new Ono drug deal

December 14, 2017
Life sciences

Bristol-Myers Squibb has licensed a phase 1 immuno-oncology med from Japan’s Ono in a $40 million upfront pact.

This geographically complex deal, which builds on a collab the pair have had for a number of years now, sees Bristol-Myers solely responsible for the development, manufacturing and commercialization of ONO-4578, Ono’s selective Prostaglandin E2 (PGE2) receptor 4 (EP4) antagonist. This program is aimed at targeting immuno-suppressive factors in the tumor microenvironment.

It also includes other PGE2 receptor antagonist products in all countries of the world except Japan, South Korea, Taiwan, China and Association of Southeast Asian Nations (ASEAN) countries.

Under the deal, Osaka-based Ono can on top of the $40 million look forward to unspecified biobucks in the form of clinical, regulatory and sales-based milestone payments, as well as royalties in these countries where BMS has exclusive license.

In Japan, South Korea and Taiwan, Bristol and Ono will partner on the development and commercialization under the companies’ existing collaboration agreement, while in China and ASEAN countries, Ono will retain exclusive rights. The focus of development appears to be across a range of tumors as BMS says that this med: “Strengthens Bristol-Myers Squibb’s oncology development program with potential to expand and enhance the benefit of immunotherapy in a broad range of tumor indications.”

“To improve long-term outcomes for more patients with cancer, we believe more immuno-oncology based combinations may be required, and we are pleased to continue our long-standing collaboration with Ono with this focus in mind,” said Fouad Namouni, M.D., head of development, oncology, at BMS.

“Ono’s Prostaglandin E2 receptor antagonist programs offer the potential to develop targeted therapies that counteract the effects of an immunosuppressive tumor microenvironment. Researching Prostaglandin E2 receptor antagonists in combination with our oncology portfolio has the potential to result in an enhanced response in a broad range of tumors.”

Bristol has been ramping up the deals in recent years, with much spent on Padlock and Flexus, and just a few months back, BMS struck a potential multi-billion biobucks deal with for IFM Therapeutics and its new immuno-oncology approaches, including its preclinical STING (stimulator of interferon genes) and NLRP3 agonist programs, both focused on enhancing the innate immune response for treating cancer.

This comes as BMS is looking to boost its own early-stage I-O pipeline, and as its major immuno-oncology med Opdivo (nivolumab) has suffered trial setbacks in the past year (although rivals Merck, AstraZeneca and Roche have also been beset in recent months).

“We are very pleased to collaborate with Bristol-Myers Squibb on ONO-4578, an innovative Immuno-Oncology therapy candidate derived from our long-standing Prostaglandin projects, and to further work with Bristol-Myers Squibb on other Prostaglandin E2 receptor antagonist programs,” added Hiroshi Awata, VP and executive director, clinical development, at Ono.

“We are committed to further pursuing the worldwide development of ONO-4578 with Bristol-Myers Squibb with the goal of improving outcomes of patients suffering from cancer around the world as promptly as possible.”

Ono, too, has been doing tie-ups, and last year struck a $300 million deal with Celyad for the rights to its allogeneic NKR-2 T-cell immunotherapy in Japan, Korea and Taiwan.

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).